To receive all of TheraVet’s financial information in real time, send a request by email to [email protected]
Gianni Pertici Ph.D., Managing Director of Industrie Biomediche Insubri SA comments: “IBI believes in regenerative medicine as the future of healthcare. With over 10 years of experience in human regeneration technologies, we firmly believe that now is the right time to invest and expand our portfolio to veterinary applications. After several months of investigation, IBI recognizes in TheraVet SA the ideal and most solid partner to take this important step. »
Enrico Bastianelli, Managing Director of TheraVet, concludes: “Following the recent arrival of a wide range of synthetic bone substitutes in the BIOCERA-VET portfolio, this partnership constitutes a new major step to position TheraVet as the undisputed leader in bone substitutes. veterinary bones. We look forward to our collaboration with IBI”.